HealthTree

A Pilot Study of Romosozumab Efficacy and Safety for the Management of Myelomarelated OsteoLytic Dis...

The purpose of this study is to measure the effect of romosozumab on bone formation and breakdown (resorption) and determine if romosozumab is a safe treatment for osteoporosis and myeloma-related bone disease (MBD) in postmenopausal people with mult...

Drug: Romosozumab

Systematic Light Exposure Effects on Circadian Rhythms Entrainment, Inflammation, Neutropenic Fever ...

The aim of this multi-site randomized control trial will be is to assess the impact Systematic lighting on circadian rhythm entrainment, Inflammation, Neutropenic Fever and Symptom Burden among Multiple Myeloma Patients undergoing Autologous Stem Cel...

Device: Circadian Effective Lighting

Device: Circadian Ineffective Lightning (CIL)

A Phase 1, Multicenter, Open-Label Study of CB-011, a CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell ...

This is a Phase 1 study to evaluate the safety of CB-011 (the study treatment), an allogeneic chimeric antigen receptor (CAR-T) cell therapy that targets the B cell maturation antigen (BCMA), to determine the best dose of CB-011, and to assess the ef...

Biological: CB-011

A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VP301 in Patients With...

This study will test the safety, tolerability, and pharmacokinetics of VP301 in patients with relapsed or refractory multiple myeloma, lymphoma, or solid tumors.

Drug: VP301

A PHASE 1B, OPEN-LABEL STUDY OF ELRANATAMAB IN COMBINATION WITH CARFILZOMIB PLUS DEXAMETHASONE IN PA...

The purpose of this study is to understand the effects of elranatamab plus carfilzomib and dexamethasone for the treatment of people with multiple myeloma. Multiple myeloma is a form of cancer in the bone that forces healthy blood cells out. The inve...

Drug: Elranatamab

Drug: Carfilzomib

A Phase 1 Study of KTX-1001, an Oral, First-In-Class, Selective, and Potent MMSET Catalytic Inhibito...

A Phase I study to evaluate the safety of a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1) to prevent the dimethylation of H3K36 in adult patients with...

Drug: KTX-1001

A Phase 1/2a Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynami...

The main aim of this study is to determine safety and tolerability of modakafusp alfa given together with daratumumab to find out the best treatment dose. Another aim of this study is to learn more about the characteristics of modakafusp alfa.

Drug: Modakafusp Alfa

Drug: Daratumumab

A Phase 1b Clinical Trial of Anti-BCMA Chimeric Antigen Receptor T Cells for Treatment of Relapsed o...

This is an open-label study to determine the safety of anti-B-cell maturation antigen (BCMA) Chimeric antigen receptor T-cell (CAR T) therapy in participants with Relapsed or Refractory Multiple Myeloma (RRMM).

Biological: Manufactured Anti-BCMA CAR-T cells

Drug: Fludarabine

Drug: Cyclophosphamide

A Phase 2, Randomized, Open-Label Study to Assess the Safety and Efficacy of GPC 100 and Propranolol...

This is a randomized, open-label study. Patients will be screened within 28 days prior to the study drug administration. Patients will be randomly assigned to 1 of 2 treatment arms prior to study drug administration. Approximately 40 patients will b...

Drug: GPC-100

Drug: Propranolol

Drug: G-CSF

A Multicenter Phase 1-DEC (Dose Expansion Cohort) Open-label Study of Iberdomide (CC-220) in Combina...

This is a single-arm, open-label study evaluating the safety, tolerability and efficacy of Iberdomide (CC-220) in combination with Elotuzumab and Dexamethasone in patients with RRMM. The researchers hypothesize that the combination of Iberdomide and ...

Drug: Iberdomide

Drug: Elotuzumab

Drug: Dexamethasone

Belantamab Mafodotin in Combination With Nirogacestat in Patients With Relapsed or Refractory Multip...

The purpose of this study is to find out whether combination treatment with the study drugsbelantamab mafodotin and nirogacestat is a safe treatment for people who have relapsed orrefractory multiple myeloma. The researchers will test different doses...

Drug: Belantamab Mafodotin

Drug: Nirogacestat

A Phase 1b Open-label Study to Evaluate the Safety and Tolerability of Intravenous Modakafusp Alfa a...

The main aims of this study is to test for any side effects from modakafusp alfa in combination therapy and to determine the recommended dose of combination therapy with modakafusp. The dose of modakafusp alfa will be increased a little at a time unt...

Drug: Modakafusp alfa

Drug: Lenalidomide

Drug: Bortezomib

Drug: Carfilzomib

Drug: Daratumumab

Drug: Pomalidomide

A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing CC-92480 (BMS-986348), Car...

The purpose of the study is to compare CC-92480 (BMS-986348) with carfilzomib and dexamethasone (480Kd) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM.

Drug: CC-92480

Drug: Carfilzomib

Drug: Dexamethasone

A Phase I/II, Open-Label, Multi-Cohort Study to Evaluate the Efficacy and Safety of Cevostamab in Pr...

This study will evaluate the efficacy, safety, and pharmacokinetics of cevostamab in participants with refractory multiple myeloma (R/R MM) via intravenous (IV) infusion.

Drug: Cevostamab

Drug: Tocilizumab

Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple M...

The purpose of this research is to determine whether the combination of selinexor, venetoclax, and dexamethasone therapy can increase anti-cancer effects in patients with translocation 11;14-positive (t(11;14)), relapsed/refractory myeloma (RRMM).

Drug: Selinexor

Drug: Venetoclax

Drug: Dexamethasone

A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing CC-92480, Bortezomib and D...

The purpose of this study is to compare the efficacy and safety of CC-92480, bortezomib and dexamethasone (480Vd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received...

Drug: CC-92480

Drug: Pomalidomide

Drug: Bortezomib

Drug: Dexamethasone

Immuno-PRISM (PRecision Intervention Smoldering Myeloma): A Randomized Phase II Platform Study of Se...

The purpose of this study is to test the anti-cancer activity of Teclistamab and to compare it with Lenalidomide + Dexamethasone combination in people with high risk smoldering multiple myeloma. People with smoldering multiple myeloma (SMM) usually ...

Drug: Teclistamab

Drug: Lenalidomide

Drug: Dexamethasone

A Phase 3 Randomized Study Comparing Talquetamab in Combination With Daratumumab (SC) and Pomalidomi...

The purpose of the study is to compare the efficacy of talquetamab subcutaneous(ly) (SC) in combination with daratumumab SC and pomalidomide (Tal-DP) and talquetamab SC in combination with daratumumab SC (Tal-D), respectively, with daratumumab in com...

Drug: Talquetamab

Drug: Daratumumab

Drug: Pomalidomide

Drug: Dexamethasone

Phase Ib/II Trial Of Iberdomide-Combinations In Patients With Positive Minimal Residual Disease (>10...

Similar to the paradigm established in other hematologic malignancies that are considered curable, the achievement of MRD(-) status is necessary for long term disease control in MM. The fact that the majority of patients remain MRD (+) after inductio...

Drug: Iberdomide

Drug: Daratumumab

Drug: Dexamethasone

Drug: Carfilzomib

Phase I Trial of Concurrent Administration of GPRC5D-Targeted CAR T Cell MCARH109 and BCMA-Targeted ...

A sample of participants' T cells will be sent to a laboratory, where the cells will be made into the study therapy, MCARH109 and MCARH125. Participants will receive either MCARH125 alone or MCARH125 with MCARH109.

Biological: MCARH125

Biological: MCARH109

A Randomized Phase 2 Trial Investigating the Impact of Budesonide Prophylaxis on Incidence of ≥ Grad...

A randomized placebo controlled, phase 2 study of budesonide in subjects with multiple myeloma undergoing autologous stem cell transplant (ACST). The study includes a run-in period with 20 patients.

Drug: Budesonide EC

Drug: Placebo

A Phase II Study of CART-ddBCMA for the Treatment of Patients With Relapsed or Refractory Multiple M...

A Phase II study of CART-ddBCMA for patients with relapsed or refractory multiple myeloma. CART-ddBCMA is a BCMA-directed CAR-T cell therapy

Biological: CART-ddBCMA

Feasibility Trial of Autologous Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Ther...

The purpose of this study is to see if the quality of T cells used to create ide-cel (bb2121) affects how ide-cel prevents cancer from coming back in people with relapsed or refractory multiple myeloma (MM), and who have had a hematopoietic cell tran...

Biological: Ide-cel (bb2121)

An Exploratory Phase 1b/2a Multicenter, Open-Label, Novel-Novel Combination Study to Assess the Safe...

The purpose of this study is to assess the safety, tolerability and preliminary effectiveness of CC-92480 (BMS-986348) in novel therapeutic combinations for the treatment of Relapsed or Refractory Multiple Myeloma (RRMM).

Drug: CC-92480

Drug: Tazemetostat

Drug: BMS-986158

Drug: Trametinib

Drug: Dexamethasone

Phase II Multicenter Trial of Iberdomide as Maintenance Therapy for Multiple Myeloma Patients With S...

The purpose of this study is to see if iberdomide is a safe and effective maintenance therapy option for people with Multiple Myeloma (MM) who have had an Autologous Hematopoietic Stem Cell Transplant (AHCT) and have already had lenalidomide as maint...

Drug: Iberdomide

A Safety and Efficacy Study of JNJ-68284528 (Ciltacabtagene Autoleucel) Out-of-Specification (OOS) f...

The purpose of this study is to evaluate the efficacy and safety of cilta-cel out-of-specification (OOS).

Drug: Cilta-cel

Drug: Lymphodepleting Therapy (Cyclophosphamide and Fludarabine)

Randomized Phase 2 Trial of Isatuximab During Autologous Stem Cell Collection and Transplantation Pe...

The purpose of this study is to see if Isatuximab can alter the immune system in patients with multiple myeloma or lymphoma upon recovery from the autologous stem cell transplantation. The investigators will see if Isatuximab makes changes to the imm...

Drug: Isatuximab

Other: Standard Procedures

Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease ...

This is a phase II study where patients will undergo isatuximab and lenalidomide maintenance starting at day 90 (+/-30 days) after Autologous Stem Cell Transplant (ASCT) provided they have achieved at least Partial Response (PR).Patients may have rec...

Drug: Isatuximab

Drug: Lenalidomide

A Phase 1b Study of Bispecific T Cell Redirection Antibodies in Combination With Checkpoint Inhibiti...

The purpose of the study is to identify the safe dose(s) of a PD-1 inhibitor in combination with talquetamab or teclistamab, and to characterize the safety and tolerability of talquetamab or teclistamab when administered in combination with a PD-1 in...

Drug: Talquetamab

Drug: Teclistamab

Drug: PD-1 Inhibitor

Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Recep...

This study is a Phase II study to determine the preliminary safety and efficacy of salvage radiation treatment after BCMA CAR-T therapy in subjects with RRMM. The study population will consist of subjects with RRMM previously treated with SOC BCMA C...

Drug: Radiation Therapy

First-in-Human Study of the BCL-2 Inhibitor ABBV-453 in Biomarker-Selected Subjects With Relapsed or...

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of ABBV-453 in adult participants with relapsed/refractory (R/R) MM. ...

Drug: ABBV-453

Study of EOS884448 Alone, and in Combination With Iberdomide With or Without Dexamethasone, in Parti...

This is a multicenter, open-label, phase I/II clinical study, to assess the safety, tolerability, antitumor activity, pharmacokinetics and pharmacodynamics of EOS884448 (also known as EOS-448 or GSK4428859A), alone or in combination with iberdomide w...

Drug: EOS884448

Drug: Iberdomide

Drug: Dexamethasone

A Dose Escalation and Expansion Study of ABBV-383 in Combination With Anti-Cancer Regimens for the T...

Multiple myeloma (MM) is a plasma cell disease characterized by the growth of clonal plasma cells in the bone marrow. The purpose of this study is to assess the safety and toxicity of ABBV-383 when co-administered with pomalidomide-dexamethasone (Pd)...

Drug: ABBV-383

Drug: Dexamethasone

Drug: Lenalidomide

Drug: Pomalidomide

Drug: Nirogacestat

Drug: Daratumumab

An Open-label Phase 1b Study of ORIC-533 in Patients With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to establish the Recommended Phase 2 Dose (RP2D), safety, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antimyeloma activity of ORIC-533 in patients with multiple myeloma who have exhausted available treat...

Drug: ORIC-533

A Phase I/II Study of Carfilzomib, Iberdomide (CC-220) and Dexamethasone (KID) in Patients With Newl...

This is a multi-institution, open label, phase I/II study of Iberdomide, Carfilzomib, and dexamethasone (KID) in patients with newly diagnosed transplant eligible MM.

Drug: Carfilzomib

Drug: Iberdomide

Drug: Oral Dexamethasone

Free From Maintenance Drug Therapy in Multiple Myeloma (The FREEDMM Trial): A Pilot Study of Minimal...

A pilot study to assess the risk of progression after stopping post-autologous stem cell transplant (ASCT) maintenance therapy in Minimal Residual Disease (MRD)-negative MM patients.

Other: Discontinue maintenance therapy SOC

Phase II Study of Pembrolizumab in Multiple Myeloma Patients Relapsing After or Refractory to Anti-B...

This phase II trial tests whether pembrolizumab works to shrink tumors in patients with multiple myeloma whose cancer has come back (relapsed) or did not respond to previous treatment (refractory) with anti-BCMA CAR-T therapies. Immunotherapy with pe...

Biological: Pembrolizumab

A Phase I Study of FT576 as Monotherapy and in Combination With Daratumumab in Subjects With Relapse...

This is a Phase I dose-finding study of FT576 as monotherapy and in combination with the monoclonal antibody daratumumab in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage.

Drug: FT576 (Allogenic CAR NK cells with BCMA expression)

Drug: Cyclophosphamide

Drug: Fludarabine

Drug: Daratumumab

Phase 2 Study of Iberdomide Maintenance Therapy Following Autologous Stem Cell Transplant in Patient...

This is a phase II study to determine the feasibility, safety and efficacy of iberdomide maintenance therapy post-ASCT. Iberdomide will be dosed at 1.0 mg PO daily for days 1-21 of a 28-day cycle. Treatment will continue until disease progression or ...

Drug: Iberdomide

A Phase 2 Study of PHE885, B-cell Maturation Antigen (BCMA)- Directed CAR-T Cells in Adult Participa...

This is a Phase II study to determine the efficacy and safety of PHE885, a BCMA-directed CAR-T cell therapy, manufactured with a new process. The CAR-T cell therapy will be investigated as a single agent in relapsed and refractory multiple myeloma

Biological: PHE885

A Phase 1 First-in-human Dose-escalation and Dose-expansion Study of BMF-219, an Oral Covalent Menin...

A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-219, an oral covalent menin inhibitor, in adult patients with acute myeloid leukemia, acute lymphocytic leukemia with KMT2A/ MLL1r, NPM1 and other mutations.

Drug: BMF-219

Phase 2 Study of Isatuximab Plus Lenalidomide and Dexamethasone in Highly Toxicity-vulnerable Subjec...

This research study is investigating the safety and effectiveness of using combination of isatuximab, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma (MM). The study team will use lower doses than is currently sta...

Drug: Isatuximab

Drug: Lenalidomide

Drug: Dexamethasone

A Phase Ib Study Of The Combination Of CD47 Blockade With SIRP-Alpha FC Fusion Proteins (TTI-622) An...

This study will test the safety of TTI-622 in combination with daratumumab hyaluronidase-fihj in people with relapsed/refractory multiple myeloma. The researchers look for the highest dose TTI-622 that causes few or mild side effects in participants ...

Drug: TTI-622

Drug: Daratumumab Hyaluronidase-fihj

Pilot Trial of Plinabulin and Pegfilgrastim to Reduce the Duration of Absolute Neutropenia After Aut...

This study will see how long it takes for white blood cell counts to return to normal in people with multiple myeloma (MM) who receive plinabulin and pegfilgrastim after undergoing an autologous hematopoietic stem cell transplant (AHCT).

Drug: Plinabulin

A Phase 1/1b, Open-Label, Multi-Center, Two-Part Study of SETD2 Inhibitor EZM0414 in Subjects With R...

This is a first-in-human (FIH), 2-part, open-label, multi-center, Phase 1/1b safety, tolerability, pharmacokinetics (PK), and efficacy study of oral SETD2 inhibitor, EZM0414, in subjects with relapsed/refractory (R/R) Multiple Myeloma (MM) and R/R Di...

Drug: EZM0414

A Multicenter Phase II Study of Maintenance Belantamab Mafodotin (Blenrep®) After BCMA-Directed Chim...

This is a multicenter phase II, open-label study evaluating the efficacy and safety of belantamab mafodotin maintenance in participants with relapsed and/or refractory multiple myeloma (RRMM) who have received commercially available anti-BCMA CAR-T-c...

Drug: Belantamab mafodotin

Phase I/IIa Study of Descartes-25 in Patients With Relapsed/Refractory Multiple Myeloma

This is a Phase I/IIa dose-escalation study to evaluate the safety, tolerability, and preliminary efficacy of an allogeneic Mesenchymal Stem Cell (Descartes-25) product secreting a bispecific protein and other proteins in patients with Relapsed/Refra...

Drug: Descartes-25

A PHASE 1B/2, OPEN LABEL UMBRELLA STUDY OF ELRANATAMAB (PF-06863135), A B-CELL MATURATION ANTIGEN (B...

The purpose of this study is to determine the Recommended Phase 2 Dose and clinical benefit of elranatamab in combination with other anti-cancer therapies in participants with multiple myeloma.

Drug: Elranatamab + Nirogacestat

Drug: Elranatamab + lenalidomide + dexamethasone

A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC (Tec-Dara) Versu...

The purpose of this study is to compare the efficacy of teclistamab daratumumab (Tec-Dara) with daratumumab subcutaneously (SC) in combination with pomalidomide and dexamethasone (DPd) or daratumumab SC in combination with bortezomib and dexamethason...

Drug: Daratumumab

Drug: Pomalidomide

Drug: Dexamethasone

Drug: Bortezomib

Drug: Teclistamab

Belantamab Mafadotin Maintenance Therapy After Salvage Autologous Hematopoietic Cell Transplantation...

The goal of this clinical research study is to learn if belantamab mafodotin (Blenrep) can help to prevent multiple myeloma (MM) from coming back after patients have had an autologous stem cell transplant (AutoSCT). The safety of this drug after tran...

Drug: Belantamab mafodotin

A Phase 2, Randomized, Parallel, Open-label Study to Investigate the Safety, Efficacy, and Pharmacok...

This study aims to evaluate alternative dosing regimens of single-agent belantamab mafodotin in participants with relapsed or refractory multiple myeloma (RRMM) to determine if an improved overall benefit/risk profile can be achieved by modifying the...

Drug: Belantamab mafodotin

A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants With Multi...

The purpose of this study is to characterize the safety and tolerability of talquetamab when administered in different combination regimens and to identify the safe dose(s) of talquetamab combination regimens.

Drug: Talquetamab

Drug: Carfilzomib

Drug: Daratumumab SC

Drug: Lenalidomide

Drug: Pomalidomide

Phase II Multicenter Trial of Anti-BCMA CAR T-Cell Therapy for MM Patients With Sub-Optimal Response...

This study is designed as a Phase II, multicenter, single arm trial to assess anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptor (CAR) T-cells (bb2121) to improve post autologous hematopoietic cell transplant (HCT) responses among patien...

Drug: Lenalidomide and bb2121

A Phase 3 Randomized, Open-label Trial of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus El...

This phase 3 randomized, open-label multicenter trial will compare the efficacy, safety and the impact on health-related quality of life (HR-QoL) of SPd versus EloPd in pomalidomide-naïve patients with MM who have received 1 to 4 prior anti-MM regime...

Drug: Selinexor

Drug: Elotuzumab

Drug: Pomalidomide

Drug: Dexamethasone Oral

A Phase I Dose Escalation Study of NMS-03597812, a PERK Inhibitor, in Adult Patients With Relapsed o...

This is a Phase I, first-in-human (FIH), open-label, non-randomized, multi-center study to explore the safety, tolerability, pharmacokinetics and preliminary antitumor activity of NMS-03597812 in adult patients with RRMM who have exhausted standard t...

Drug: NMS-03597812

Drug: NMS-03597812 + dexamethasone

A Phase I Clinical Trial With TriPRIL CAR T Cells for the Treatment of Patients With Relapsed or Ref...

This research study involves the study of TriPRIL CAR T Cells for treating people with relapsed or refractory multiple myeloma and to understand the side effects when treated with TriPRIL CAR T Cells. This research study involves the study drugs:. ...

Drug: TriPRIL CAR T Cells

Drug: Cyclophosphamide

Drug: Fludarabine

A PHASE 1/2, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE A DOSING REGIMEN WITH TWO STEP-UP PRIMING DOS...

The purpose of Part 1 and Part 2 is to evaluate the safety of a step-up dosing approach (starting with low doses followed by higher doses) of the study medicine (elranatamab) in participants with multiple myeloma that has come back after responding t...

Drug: Elranatamab

Drug: Elranatamab+ dexamethasone

A Pilot Study to Assess Impact of Low Dose Melphalan on Disease Burden Measured by Next Generation S...

The purpose of this study is to see if Multiple Myeloma (MM) cells are sensitive to the chemotherapy used in transplant or not. The main chemotherapy agent utilized in stem cell transplant is melphalan. The study will utilize 1/10 of the dose used in...

Drug: Evomela

Device: Next Generation Sequencing

Drug: Prochlorperazine

Drug: Acetaminophen

Drug: Diphenhydramine

A Phase 1b, Open-Label Study of the Safety and Efficacy of Allogeneic Anti-CD38 A2 Dimeric Antigen R...

This is a phase 1b, open-label, dose-escalation study of STI-1492 administered by a single intravenous infusion in subjects with relapsed or refractory multiple myeloma.

Biological: STI-1492

Novel Combination of Belantamab Mafodotin and Elotuzumab to Enhance Therapeutic Efficacy in Multiple...

The purpose of this research study is to determine if two drugs approved for treating multiple myeloma, belantamab mafodotin and elotuzumab, are safe and more effective when used together.

Drug: Elotuzumab

Drug: Belantamab mafodotin

A Single-Arm, Open-Label, Phase 1/2 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pha...

The purpose of the ALLO-605-201 study is to assess the safety, efficacy, and cell kinetics of ALLO605 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide, and ALLO-647.

Genetic: ALLO-605

Biological: ALLO-647

Drug: Fludarabine

Drug: Cyclophosphamide

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia - MILESTONE Trial

This is a phase II interventional study evaluating the use of minimal residual disease by next generation sequencing to defer autologous hematopoietic stem cell transplantation (AHCT) in patients with newly diagnosed multiple myeloma.

Drug: DaraVRD

A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab an...

This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in ...

Drug: Dexamethasone

Drug: Daratumumab

Drug: Bortezomib

Drug: Iberdomide

A Phase II Pilot Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome ...

This study will evaluate the use of siltuximab to decrease the severity of cytokine release syndrome (CRS) and immune effector cell-associated neurological syndrome (ICANS) in patients who will receive chimeric antigen receptor (CAR) T-cell therapy f...

Drug: Siltuximab

A Phase 1, Multi-center, Open-label, Dose Finding Study of CC-92328 in Subjects With Relapsed and/or...

This Phase 1, first-in-human (FIH), clinical study of CC-92328 will explore the safety, tolerability and preliminary biological and clinical activity of CC-92328 as a single-agent in the setting of relapsed and/or refractory multiple myeloma (R/R MM)...

Drug: CC-92328

A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-...

Study consists of two parts, a part 1 dose escalation and a part 2 cohort expansion in combination with dexamethasone and carfilzomib intravenously across two cohorts with a monotherapy component as well.

Drug: BGB-11417

Drug: Dexamethasone

Drug: Carfilzomib

Open-Label, Multicenter, Phase 1 Study to Assess the Safety of P-BCMA-ALLO1 in Subjects With Relapse...

Phase 1 study comprised of open-label, dose escalation, multiple cohorts of P-BCMA-ALLO1 allogeneic T stem cell memory (Tscm) CAR-T cells in subjects with relapsed / refractory Multiple Myeloma (RRMM).

Biological: P-BCMA-ALLO1 CAR-T cells

Drug: Rimiducid

A Phase Ib/II Open-Label Study of APG-2575 in Combination With Novel Therapeutic Regimens in Subject...

This is a Phase Ib/II, open-label, multi-center study evaluating the safety, tolerability, efficacy, and PK/ Pharmacodynamics of APG-2575 in combination with Pd/DRd in patients with relapsed/refractory (RR) multiple myeloma (MM). The study consists o...

Drug: APG-2575+ Pd

Drug: APG-2575 + DRd

A Phase 2 Adaptive Study of Subcutaneous Daratumumab, Once Weekly Carfilzomib, and Dexamethasone (DK...

Background: Multiple myeloma (MM) is a tumor in which malignant plasma cells accumulate in the bone marrow. It can cause organ damage and is not curable. Researchers want to see if a combination drug treatment can help. Objective: To try to preven...

Drug: Dexamethasone

Drug: Carfilzomib

Biological: Daratumumab

Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

Selinexor (KPT-330, Xpovio) is a first in class selective inhibitor of nuclear export which has been approved for use in relapsed and refractory multiple myeloma (RRMM). This trial will seek to evaluate the outcomes achieved with selinexor based comb...

Drug: Selinexor

Drug: Pomalidomide

Drug: Daratumumab

Drug: Carfilzomib

Drug: Dexamethasone

A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Ci...

The purpose of this study is to compare the efficacy of Bortezomib, Lenalidomide and Dexamethasone (VRd) induction followed by a single administration of ciltacabtagene autoleucel (cilta-cel) versus VRd induction followed by Lenalidomide and Dexameth...

Drug: Bortezomib

Drug: Dexamethasone

Drug: Lenalidomide

Drug: Cilta-cel

Drug: Cyclophosphamide

Drug: Fludarabine

Promoting Physical Activity to Improve Cognitive Function in Older Adults Undergoing Hematopoietic C...

Cancer and treatment-related cognitive changes hinder resumption of normal routine and roles and worsen quality of life. Older adults undergoing hematopoietic cell transplantation (HCT) are at high-risk for cognitive impairment. Physical activity imp...

Behavioral: CHAMPS-II adapted to adults 60+ years in HCT setting

Other: Survivorship education active control

Belantamab Mafodotin, Cyclophosphamide and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Evaluate the efficacy and safety of Belantamab Mafodotin, cyclophosphamide, and dexamethasone in patients with Relapsed/Refractory Multiple Myeloma

Drug: Belantamab Mafodotin, Cyclophosphamide and Dexamethasone

A Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple M...

The goal of this clinical study is to learn more about the safety and dosing of the study drug, magrolimab, in combination with other anticancer therapies in participants with relapsed/refractory multiple myeloma.

Drug: Magrolimab

Drug: Daratumumab

Drug: Pomalidomide

Drug: Dexamethasone

Drug: Bortezomib

Drug: Carfilzomib

A Phase 1/2a Open-label Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynami...

A phase 1/2a, first-in-human trial to evaluate the safety and tolerability of LAVA-051 in patients with relapsed or refractory Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM), or Acute Myeloid Leukemia (AML).

Biological: LAVA-051

A Phase 1/2a, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Effic...

This study will assess the safety, tolerability, pharmacokinetics (PK) and the therapeutic potential of HDP-101 in patients with plasma cell disorders including multiple myeloma.

Drug: HDP-101

An Exploratory Phase 1/2 Trial to Determine Recommended Phase 2 Dose (RP2D), Safety and Preliminary ...

This is a global, open-label, multi-arm, multi-cohort, multi-center, phase 1/2 study to determine the safety, tolerability, efficacy, PK of bb2121 in combination with other therapies in adult subjects with R/RMM. The following combinations will be ...

Biological: BB2121

Drug: CC-220

Drug: BMS-986405

A Randomized Placebo-Controlled Phase 2 Study of Metformin for the Prevention of Progression of Mono...

The purpose of this research is to understand whether the drug metformin could be used in the future to help prevent patients with monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) from developing multipl...

Drug: Metformin XR

Other: Placebo

A Multisite, Phase II Study of Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed an...

This is a multicenter, open-label phase II study in subjects with relapsed and/or refractory multiple myeloma with at least two prior lines of therapy. The main study consists of three phases: a 28-day screening phase, treatment phase that consists o...

Drug: Isatuximab (for run-in portion)

Drug: Isatuximab (for expansion)

Drug: Pomalidomide

Drug: Elotuzumab

Drug: Dexamethasone

An Open-Label, Multicenter, Phase 1/2 Trial of GEN3014 (HexaBody®-CD38) in Relapsed or Refractory Mu...

The drug that will be investigated in the study is an antibody, GEN3014. Since this is the first study of GEN3014 in humans, the main purpose is to evaluate safety. Besides safety, the study will determine the recommended GEN3014 dose to be tested in...

Biological: GEN3014

Drug: Daratumumab

A Phase I/II Study of Carfilzomib, Lenalidomide, Dexamethasone and the Anti-B-Cell Maturation Antige...

This research study is being done to learn if the study drug belantamab mafodotin, in combination with other standard medications, can improve multiple myeloma. This study will also help determine what effects, good and/or bad, this combination of st...

Drug: Carfilzomib, Lenalidomide, Dexamethasone, Belantamab Mafodotin

A Phase II Trial of Daratumumab, Lenalidomide and Dexamethasone (DRd) in Combination With Selinexor ...

This is a single-arm, phase II, open-label trial to investigate the effects of selinexor (S) in combination with daratumumab, lenalidomide, and dexamethasone (DRd) for first-line treatment of multiple myeloma (MM). FDA has approved selinexor plus de...

Drug: Selinexor

Drug: Dexamethasone Oral

Drug: Daratumumab

Drug: Lenalidomide

A Phase 1b/2 Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of TAK-981 in Combina...

TAK-981 is being tested in combination with anti-CD38 monoclonal antibodies (mAbs) to treat participants who have relapsed or refractory multiple myeloma (RRMM). The main aims of the study are to evaluate the safety and efficacy of TAK-981 in combin...

Drug: TAK-981

Drug: Mezagitamab

Drug: Daratumumab and Hyaluronidase-fihj

B- PRISM (Precision Intervention Smoldering Myeloma): A Phase II Trial of Combination of Daratumumab...

The purpose of this research study is to learn whether the combination of daratumumab SC ( Darzalex Faspro), lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone works in treating smoldering multiple myeloma and preventing progression to a...

Drug: Daratumumab

Drug: Bortezomib

Drug: Lenalidomide

Drug: Dexamethasone

A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination With AB122 in Par...

This is a Phase 1/1b, multicenter, open-label, dose-escalation, and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and clinical activity of AB308 in combination with zimberelimab (AB122) in part...

Drug: AB308

Drug: Zimberelimab

A Phase 1/1b Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of LP-118 in Su...

This is a Phase 1, multi-center, open-label study with a dose-escalation phase (Phase 1a) and a cohort expansion phase (Phase 1b), to evaluate the safety, tolerability, and PK profile of LP-118 under a once daily oral dosing schedule in up to 100 sub...

Drug: LP-118

A Phase 1/2 Open-Label Multi-Center Study to Characterize the Safety and Tolerability of CFT7455 in ...

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of CFT7455 administered orally in subjects with Relapsed/Refractory (r/r) Non-Hodgkin's Lymphoma (NHL) or Multiple Myelo...

Drug: CFT7455

Drug: Dexamethasone Oral

Efficacy of Curcumin and Piperine in Patients on Active Surveillance for Either Monoclonal Gammopath...

To explore the use of curcumin and piperine supplementation at a dose of 4 gram/5mg twice a day in early stage prostate cancer patient undergoing active surveillance or patients on observation for MGUS/ low-risk smoldering myeloma.

Drug: Curcumin plus Piperine

A Phase Ib, Multicenter Study of VOB560 in Combination With MIK665 in Patients With Relapsed/Refract...

The purpose of the study is to identify doses and schedules of VOB560 and MIK665 that can be safely given and to learn if the combination can have possible benefits for patients with Non-Hodgkin lymphoma (NHL), Multiple Myeloma (MM) or Acute Myeloid ...

Drug: VOB560

Drug: MIK665

A Multi-Center Phase 2 Study of Daratumumab With Pomalidomide and Dexamethasone in Combination With ...

The purpose of this study is to test the safety and efficacy of the study drug daratumumab, when given together with Pomalidomide, Dexamethasone, and All-Transretinoic Acid (ATRA).

Drug: Daratumumab

Drug: Pomalidomide

Drug: All-trans retinoic acid

Drug: Dexamethasone

A Phase 1, Multicenter, Open-Label Study of CC-95266 in Subjects With Relapsed and/or Refractory Mul...

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-95266 in participants with relapsed and/or refractory multiple myeloma (R/R MM).

Drug: CC-95266

Drug: Fludarabine

Drug: Cyclophosphamide

Drug: Bendamustine

A Phase 2B Study of Selinexor (KPT-330), in Combination With Carfilzomib, Daratumumab or Pomalidomid...

This is a prospective, 2-arm (with an additional exploratory arm), open-label, multicenter study looking at the response rate of patients receiving selinexor (KPT-330), in combination with carfilzomib, daratumumab or pomalidomide. Multiple Myeloma p...

Drug: Selinexor 60 MG

Drug: Selinexor 80 MG

Drug: Selinexor 100 MG

Drug: Carfilzomib

Drug: Pomalidomide

Drug: Daratumumab

Drug: Dexamethasone

Phase 2, Multi-Center, Single-Arm, Open-Label Study to Evaluate the Efficacy and Safety of the Combi...

This research is testing whether the investigational drug isatuximab is safe and effective when used in combination with standard agents for the treatment of newly diagnosed multiple myeloma.

Drug: Isatuximab

Drug: Lenalidomide

Drug: Bortezomib Injection

Drug: Dexamethasone

A Phase II Study of Steroid Sparing Treatment With Daratumumab and Lenalidomide in Newly Diagnosed T...

The purpose of this study is to determine the effects of daratumumab and lenalidomide without steroids for treating patients with multiple myeloma.

Drug: Daratumumab

Drug: Lenalidomide

Drug: Dexamethasone

A Phase 1 Study of Autologous Memory-like Natural Killer (NK) Cell Immunotherapy With BHV-1100 (Form...

This is an open-label single center Phase 1a/1b study with the primary objective of establishing the safety and exploring the efficacy of infusing the ex vivo combination product of cytokine induced memory-like (CIML) NK cells plus KP1237 and low dos...

Combination Product: CIML NK Cells plus KP1237 and low dose IL-2

A Phase I, Open-Label, Multicenter Study of FT538 as Monotherapy in Relapsed/Refractory Acute Myelog...

This is a Phase I dose-finding study of FT538 as monotherapy in acute myeloid leukemia (AML) and in combination with monoclonal antibodies in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage where partic...

Drug: FT538

Drug: Cyclophosphamide

Drug: Fludarabine

Drug: Daratumumab

Drug: Elotuzumab

A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participan...

This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy in participants with MDS or MM who are transfusion-dependent or present with symptomati...

Drug: INCB000928

A Pilot Study Examining Selinexor's Ability to Overcome Resistance in Multiple Myeloma Patients Who ...

This is a pilot study evaluating the safety and efficacy of selinexor among multiple myeloma (MM) patients that are refractory to lenalidomide-containing regimens with or without steroids.

Drug: Selinexor

Drug: Lenalidomide

Drug: Methylprednisolone

Daratumumab Versus Lenalidomide Maintenance Therapy for Multiple Myeloma: A Randomized Pilot Study C...

The purpose of this study is to compare maintenance therapy approaches in people with newly diagnosed multiple myeloma (MM) that has responded well to a first round of treatment. The researchers will compare giving the usual maintenance therapy (lena...

Drug: Lenalidomide

Drug: Daratumumab

Behavioral: Questionnaires

Other: Dietary Intervention

A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belant...

This study will evaluate the efficacy and safety of belantamab mafodotin in combination with pomalidomide and dexamethasone (Arm A) compared with that of combination of pomalidomide, bortezomib and dexamethasone (Arm B) in participants with relapsed/...

Drug: Belantamab mafodotin

Drug: Pomalidomide

Drug: Dexamethasone

Drug: Bortezomib

Phase 1 of Exposure Targeted Melphalan Dosing

This phase I trial studies the best dose and side effects of mephalan in treating patients with multiple myeloma who are undergoing stem cell transplant. Chemotherapy drugs, such as mephalan, work in different ways to stop the growth of cancer cells,...

Procedure: Autologous Hematopoietic Stem Cell Transplantation

Drug: Melphalan

Other: Questionnaire Administration

Opioid-Sparing Pain Treatment In Myeloma And Lymphoma Patients Undergoing High-Dose Chemotherapy (OP...

The purpose of this study is to find out whether acupuncture treatments can reduce the need for opioid medication when managing pain caused by chemotherapy. The study will compare the effects of adding acupuncture to usual pain management with those ...

Other: Acupuncture

Drug: opioid

Other: Assessments

A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Di...

This research study is testing the efficacy of an experimental drug combination for people with newly diagnosed multiple myeloma that are eligible for a stem cell transplant. The names of the study drugs involved in this study are: Carfilzomib Isat...

Drug: Carfilzomib

Drug: Isatuximab

Drug: Lenalidomide

Drug: Dexamethasone

Phase 1 Study of Tasquinimod Alone and in Combination With Standard Therapy for Relapsed or Refracto...

This study is the first study of tasquinimod, an inhibitor of S100A9, in patients with multiple myeloma.

Drug: Tasquinimod

Drug: IRd chemotherapy

A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in P...

Belantamab mafodotin is an antibody-drug conjugate (ADC) containing humanized anti- B-cell maturation antigen (BCMA) monoclonal antibody (mAb). Renal impairment is a major complication of multiple myeloma (MM) and the majority of MM participants is e...

Drug: Belantamab mafodotin

A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in P...

The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of belantamab mafodotin monotherapy in Relapsed/Refractory Multiple Myeloma (RRMM) participants with impaired hepatic function and in matched RRMM participants...

Drug: Belantamab mafodotin

A Phase 1 Study of ION251 Administered by Intravenous Infusion to Patients With Relapsed/Refractory ...

The purpose of this study is to determine the maximum-tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of ION251 in patients with relapsed/refractory multiple myeloma.

Drug: ION251

A Phase 1 Study of The Safety and Tolerability of COM902 in Subjects With Advanced Malignancies

Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies.

Drug: Dose escalation: COM902 monotherapy.

Combination Product: Evaluation of safety/tolerability: COM902 in combination with COM701 (both at the RDFE)

Drug: Cohort expansion: COM902 (RDFE) monotherapy.

Drug: Cohort expansion: COM902 in combination with COM701 (both at the RDFE).

Combination Product: Cohort expansion: Triplet combination of COM902 + COM701 + Pembrolizumab.

Phase I, Open Label, Study of B-cell Maturation Antigen (BCMA)-Directed CAR-T Cells in Adult Patient...

This is a first-in-human study to evaluate the feasibility, safety and preliminary antitumor efficacy of autologous T cells genetically engineered with a novel B-cell Maturation Antigen (BCMA)-specific chimeric antigen receptor (CAR) and manufactured...

Biological: PHE885

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multipl...

This is a single-center single-arm phase 2 study in which patients will receive daratumumab in combination with clarithromycin/pomalidomide/dexamethasone (D-ClaPd) until progressive disease (PD) or unacceptable toxicity, whichever comes first. This s...

Drug: Daratumumab

Drug: Clarithromycin

Drug: Pomalidomide

Drug: Dexamethasone

Phase 2, Open-Label Randomized Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone vs...

This study is being done to find out whether carfilzomib, lenalidomide, and dexamethasone (KRD) or KRD and Daratumumab (KRD+DARA) might be safer and more effective ways of controlling multiple myeloma than the stand or care treatment, which is lenali...

Drug: Bortezomib

Drug: Dexamethasone

Drug: Lenalidomide

Drug: Acetaminophen

Drug: Diphenhydramine

Drug: Montelukast

Drug: Carfilzomib

Drug: Daratumumab

Biological: Autologous Stem Cell Transplant (ASCT)

A Multisite, Phase II Study of Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone (VICD) Ind...

This is a single-arm, open-label phase II study with a safety lead-in phase.

Drug: Bortezomib

Drug: Isatuximab

Drug: Cyclophosphamide

Drug: Dexamethasone

A Phase 1 Open-label, Multicenter, Dose Escalation Study of the Safety, Tolerability, and Pharmacoki...

An open-label, Phase 1 study of HPN217 to assess the safety, tolerability and PK in patients with relapsed/ refractory multiple myeloma

Drug: HPN217

A Phase II Study of Daratumumab With Weekly Carfilzomib, Pomalidomide, and Dexamethasone in Relapsed...

This research study is studying the combination of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in people with relapsed and refractory multiple myeloma. Relapsed and Refractory Multiple Myeloma is the condition of returned or ...

Drug: Daratumumab

Drug: Carfilzomib

Drug: Pomalidomide

Drug: Dexamethasone

Phase II Trial of Autologous Rapamycin-Resistant Th1/Tc1 (RAPA-201) Cell Therapy of Relapsed, Refrac...

RAPA-201-RRMM is an open-label, single-arm, non-randomized multicenter phase II study of RAPA-201 autologous T cells in adults with relapsed, refractory multiple myeloma who have received at least three (3) prior lines.

Biological: RAPA-201 Autologous T cells

A Pilot Study Evaluating Lenalidomide and CC-486 in Combination With Radiotherapy For Patients With ...

The purpose of this study is to investigate if the combination of CC-486 with lenalidomide and radiation therapy is a safe and effective treatment for plasmacytoma.

Drug: CC-486

Drug: Lenalidomide

Radiation: Radiation Therapy

Master Protocol for the Phase 1 Study of Cell Therapies for the Treatment of Patients With Relapsed ...

Master protocol for cell therapy, Phase 1 proof-of-concept studies in relapsed and refractory multiple myeloma and includes long-term safety follow-up.

Drug: CART-ddBCMA

Drug: ARC-T Plus Anti-BCMA SparX

A Phase I/II Assessment of Combination Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 (BMS-986016) and...

This a Phase I/II randomized trial for patients with relapsed refractory Multiple Myeloma who have relapsed after treatment with prior therapies. The protocol is designed to evaluate two agents, Anti-LAG-3 and Anti-TIGIT, in order to understand their...

Drug: Elotuzumab, pomalidomide, dexamethasone

Drug: Anti-LAG-3

Drug: Anti-LAG-3 + Pomalidimide + Dexamethasone

Drug: Anti-TIGIT

Drug: Anti-TIGIT + Pomalidimide + Dexamethasone

Phase I, Open-label Dose-escalation Study to Evaluate the Safety, Expansion, Persistence and Clinica...

This is a Phase I, FIH, open-label, dose escalation study evaluating Safety and Efficacy of UCART targeting CS1 in patients with Relapsed or Refractory Multiple Myeloma (MM). The purpose of this study is to evaluate the safety and clinical activity o...

Biological: UCARTCS1A

Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Di...

This phase 2 trial will test whether the combination of DaraRd (daratumumab + lenalidomide + dexamethasone) as induction therapy, followed by DRVd (daratumumab + lenalidomide + bortezomib + dexamethasone) consolidation therapy, if needed, will result...

Drug: Daratumumab

Drug: Lenalidomide

Drug: Bortezomib

Drug: Dexamethasone

A Phase 2, Multicohort Open-Label Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) ...

The purpose of this study is to evaluate the overall minimal residual disease (MRD) negative rate of participants who receive JNJ-68284528.

Drug: JNJ-68284528

Drug: Lenalidomide

Drug: Daratumumab

Drug: Bortezomib

Drug: Dexamethasone

A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab ...

B-cell maturation antigen (BCMA) is a target present on tumor cells in participants with multiple myeloma. Belantamab mafodotin (GSK2857916); is an antibody-drug conjugate (ADC) containing humanized anti-BCMA monoclonal antibody (mAb). This is a phas...

Drug: Belantamab mafodotin

Drug: GSK3174998

Drug: Feladilimab

Drug: Nirogacestat

Drug: Dostarlimab

Drug: Isatuximab

Drug: Lenalidomide

Drug: Dexamethasone

Drug: Pomalidomide

Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed/or Refract...

This is a Phase I/II study using the combination of twice weekly ixazomib plus pomalidomide and dexamethasone in relapsed and or refractory multiple myeloma (RRMM) patients.

Drug: Ixazomib

Drug: Pomalidomide

Drug: Dexamethasone

A Single-Arm, Open-Label, Phase 1 Study of the Safety, Efficacy, and Cellular Kinetics/Pharmacodynam...

The purpose of the UNIVERSAL study is to assess the safety, efficacy, cell kinetics, and immunogenicity of ALLO-715 with or without Nirogacestat in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen of ALLO-647 in com...

Genetic: ALLO-715

Biological: ALLO-647

Drug: Fludarabine

Drug: Cyclophosphamide

Drug: Nirogacestat

A Phase 1, Randomized, Dose and Schedule Evaluation Study to Investigate the Safety, Pharmacokinetic...

This study will evaluate the safety, pharmacokinetics, pharmacodynamics and clinical activity of belantamab mafodotin in combination with Velcade (bortezomib), Revlimid (lenalidomide), dexamethasone (VRd) and will determine recommended phase 3 dose (...

Drug: Belantamab mafodotin

Drug: Bortezomib

Drug: Lenalidomide

Drug: Dexamethasone

S1803, Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Au...

Patients are enrolled to screening (Reg Step 1) prior to or after ASCT but prior to Reg Step 2. Patients are followed until they will begin Maintenance and then registered to Reg Step 2 (first randomization). Patients are randomized between Lenalidom...

Drug: Lenalidomide

Drug: Daratumumab/rHuPH20

A Phase 2 Study of Subcutaneous Daratumumab in Combination With Dose-Attenuated Bortezomib, Lenalido...

This is a single center, open-label, phase 2 study in elderly (age ≥ 70) subjects with newly diagnosed multiple myeloma who are transplant ineligible. Subjects will receive subcutaneous daratumumab, dose-attenuated bortezomib, revlimid, and dexametha...

Drug: Daratumumab

Drug: Bortezomib

Drug: Lenalidomide

Drug: Dexamethasone

Drug: Ixazomib

A Phase 1, Multicenter, Open-label, Dose Finding Study of CC-99712, a BCMA Antibody-Drug Conjugate, ...

Study CC-99712-MM-001 is an open-label, Phase 1, dose escalation (Part A) and expansion (Part B), First-in-Human (FIH) clinical study of CC-99712 in monotherapy or combination with BMS-986405 in participants with relapsed and refractory multiple myel...

Drug: CC-99712

Drug: BMS-986405

A Multi-Center, Open Label Phase 1/2 Study of CYT-0851 in Patients With Relapsed/Refractory B-Cell M...

This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of CYT-0851 in patients with relapsed/refractory B-cell malig...

Drug: CYT-0851

Drug: CYT-0851 in combination with gemcitabine

Drug: CYT-0851 in combination with capecitabine

Drug: CYT-0851 in combination with rituximab and bendamustine

A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evalu...

The purpose of this study is to evaluate the safety and preliminary efficacy of CC-92480 in combination with standard treatments.

Drug: CC-92480

Drug: Bortezomib

Drug: Dexamethasone

Drug: Daratumumab

Drug: Carfilzomib

Drug: Elotuzumab

Drug: Isatuximab

Drug: Carfilzomib

Open Label, Multi-center, Phase 1b/2 Clinical Trial to Evaluate the Safety and Efficacy of Autologou...

A phase 1b/2, open label, multi-center, Clinical Study of Chimeric Antigen Receptor T Cells targeting BCMA in patients with relapsed and or refractory multiple myeloma.

Biological: zevor-cel

Phase I Study of Carfilzomib-based Chemotherapy Mobilization for Autologous Stem Cell Transplantatio...

This phase I study utilizes a 3+3 design with escalating cohorts of Carfilzomib at 20mg/m2, 27mg/m2, 36mg/m2, 45mg/m2, 56mg/m2, and 70mg/m2 to be administered concomitantly with Cyclophosphamide 2 gm/m2, Dexamethasone and Granulocyte colony-stimulati...

Drug: Carfilzomib

Drug: Cyclophosphamide

Drug: Dexamethasone

Drug: Granulocyte Colony-Stimulating Factor

A Randomized Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatme...

The purpose of this study is to evaluate conversion rate to minimal residual disease (MRD) negativity following the addition of daratumumab to lenalidomide relative to lenalidomide alone, when administered as maintenance treatment to anti-cluster of ...

Drug: Daratumumab

Drug: Lenalidomide

Post-Op Pain Control for Prophylactic Intramedullary Nailing.

Nationally, the opioid crisis has become a major epidemic with increasing mortality rates each year. Orthopedic surgeons routinely prescribe narcotics instead of NSAIDs for post-op pain control because of risk of delayed healing and nonunion due to N...

Drug: Ketorolac

Drug: Normal saline

Drug: Acetaminophen

Drug: Oxycodone Acetaminophen

Drug: Morphine

Drug: Hydrocodone/Acetaminophen

Drug: Oxycodone

Phase I/II Study Utilizing High Dose Busulfan and Melphalan With Escalating Carfilzomib as Condition...

In this protocol, the investigators hypothesize that the combination of intravenous busulfan and melphalan with carfilzomib will be an effective preparative regimen with acceptable toxicity for participants with multiple myeloma who are candidates fo...

Drug: Carfilzomib

Drug: Busulfan IV

Drug: Melphalan IV

A Phase 2, Open Label, Randomized Trial Evaluating Ixazomib Compared to Ixazomib-Lenalidomide Combin...

This is a randomized, Phase 2 study involving two arms evaluating the efficacy and safety of ixazomib alone and the combination of both ixazomib and lenalidomide as maintenance therapy for patients with multiple myeloma who have achieved at least par...

Drug: Ixazomib

Drug: Lenalidomide

Myeloma-Developing Regimens Using Genomics (MyDRUG) (Genomics Guided Multi-arm Trial of Targeted Age...

The MyDRUG study is a type of Precision Medicine trial to treat patients with drugs targeted to affect specific genes that are mutated as part of the disease. Mutations in genes can lead to uncontrolled cell growth and cancer. Patients with a greater...

Drug: Abemaciclib, dexamethasone, ixazomib, pomalidomide

Drug: Enasidenib, dexamethasone, ixazomib, pomalidomide

Drug: Cobimetinib, dexamethasone, ixazomib, pomalidomide

Drug: Erdafitinib, dexamethasone, ixazomib, pomalidomide

Drug: Venetoclax, dexamethasone, ixazomib, pomalidomide

Drug: Daratumumab, dexamethasone, ixazomib, pomalidomide

Drug: Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide

Drug: Selinexor, dexamethasone, ixazomib, pomalidomide

A Randomized, Open-label Phase 3 Study of Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortez...

This is a randomized multicenter study that will compare two treatment regimens (Kyprolis, Revlimid, dexamethasone -KRD vs. Velcade, Revlimid, dexamethasone -VRD) for patients with newly diagnosed multiple myeloma.

Drug: Carfilzomib

Drug: Lenalidomide

Drug: Dexamethasone

Drug: Bortezomib

A Phase I Study of Ibrutinib (PCI-32765) in Combination With Revlimid/Dexamethasone (Rd) in Relapsed...

This is a registration, open-label phase 1 study of the combination of ibrutinib/lenalidomide:/dexamethasone in women and men with relapsed/refractory multiple myeloma.

Drug: Ibrutinib

Drug: Lenalidomide

Drug: Dexamethasone

Phase I Study of Autologous CAR T-Cells Targeting the CD138 Antigen for Relapsed or Refractory Multi...

The body has different ways of fighting infection and disease. No single way seems perfect for fighting cancer. This research study combines two different ways of fighting disease: antibodies and T cells. Antibodies are proteins that protect the body...

Drug: CAR138 T Cells

High Dose Ascorbic Acid (HDAA) in Patients With Plasma Cell Disorders

This is a Phase I single-arm open-label clinical study primarily assessing the safety and secondarily, the relative efficacy of low dose melphalan + high dose ascorbate acid (HDAA) in relapsed refractory patients with multiple myeloma.

Other: Ascorbate

Drug: Melphalan

A Phase 2, Multi-cohort, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of bb2121...

This study is a multi-cohort, open-label, multicenter Phase 2 study to evaluate the efficacy and safety of bb2121 in subjects with relapsed and refractory MM (Cohort 1), in subjects with MM having progressed within 18 months of initial treatment incl...

Biological: bb2121

Drug: Lenalomide

A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine and Melphalan (BEAM) a...

The work proposed herein aims to provide the first prospective, randomized comparative efficacy data between Melphalan and BEAM treatment regimen in the Multiple Myeloma (MM) patient population. The risk of such a study is deemed reasonable and ethic...

Drug: Allopurinol

Drug: Carmustine

Drug: Etoposide

Drug: Cytarabine

Drug: Melphalan

A Phase 3, Multicenter, Randomized, Open Label Study of Venetoclax and Dexamethasone Compared With P...

A study designed to evaluate the safety and efficacy of venetoclax plus dexamethasone (VenDex) compared with pomalidomide plus dexamethasone (PomDex) in participants with t(11;14)-positive Relapsed or Refractory Multiple Myeloma.

Drug: Pomalidomide

Drug: Dexamethasone

Drug: Venetoclax

A Phase 1a/1b Dose-Escalation and Expansion Trial of TTI-622 in Patients With Advanced Hematologic M...

The purpose of this clinical trial is to learn how the experimental medicine (TTI-622) affects people with various types of blood cancers: relapsed or refractory (R/R) lymphoma multiple myeloma newly diagnosed acute myeloid leukemia (AML). This tri...

Drug: TTI-622

Drug: Azacitidine

Drug: Venetoclax

Drug: Carfilzomib

Drug: Dexamethasone

Drug: Anti-CD20 Targeting agent

Drug: Isatuximab

Open-label, Single-arm, Phase 2 Study of Initial Treatment With Daratumumab (Darzalex), Carfilzomib ...

The purpose of this study is to determine response rate after 8 cycles of D-KRd (daratumumab, carfilzomib, lenalidomide (Revlimid) and dexamethasone in patients with multiple myeloma.

Drug: Daratumumab

Drug: Carfilzomib

Drug: Lenalidomide

Drug: Dexamethasone

A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Sub...

Study CC-93269-MM-001 is an open-label, Phase 1, dose escalation (Part A and C) and expansion (Parts B and D), first-in-human clinical study of CC-93269 in subjects with relapsed and refractory multiple myeloma.

Drug: CC-93269

A Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-...

Background: A person s tumor is studied for mutations. When cells are found that can attack the mutation in a person s tumor, the genes from those cells are studied to find the parts that make the attack possible. White blood cells are then taken fr...

Drug: Cyclophosphamide

Drug: Fludarabine

Drug: Aldesleukin

Biological: Individual Patient TCR-Transduced PBL

Drug: Pembrolizumab (KEYTRUDA )

A Phase 1/2 Multicenter, Open-label Study to Assess the Safety, Pharmacokinetics and Efficacy of CC-...

This is an open-label, multi-center, international, Phase 1/2 study to assess the safety, PK and efficacy of CC-92480 monotherapy and in combination with dexamethasone in subjects with relapsed and refractory multiple myeloma (RRMM). All eligible su...

Drug: CC-92480

Drug: Dexamethasone

Myeloablative Allogeneic Hematopoietic Cell Transplantation Using a Related or Unrelated Donor for t...

This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by...

Biological: HSCT with TBI Regimen

Biological: HSCT with Non-TBI Regimen

A Phase 1, First-in-Human, Multicenter, Open-Label, Two-Part Dose-Escalation and Cohort Expansion St...

The purpose of this study is to assess safety, efficacy, pharmacokinetic (PK)/pharmacodynamic (PD), and immunogenicity with ISB 1342 in subjects with relapsed/refractory multiple myeloma.

Biological: ISB 1342

An Open-Label, Multicenter, Phase I Trial Evaluating the Safety and Pharmacokinetics of Escalating D...

This is a phase I, multicenter, open-label, dose-escalation study of cevostamab administered as a single agent by IV infusion to participants with relapsed or refractory multiple myeloma (R/R MM).

Drug: Cevostamab

Drug: Tocilizumab

A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics,...

The main aims of this 3-part study are as follows: Part 1: To determine any side effects from modakafusp alfa single treatment and how often they occur. The dose of modakafusp alfa will be increased a little at a time until the highest dose that doe...

Drug: Modakafusp alfa

Drug: Dexamethasone

Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradi...

This is an open-label, single-arm, phase II study to determine the safety of propylene glycol-free melphalan HCl (EVOMELA®), in combination with fludarabine and total-body irradiation-based reduced-intensity conditioning for haploidentical transplant...

Drug: Evomela

Drug: Fludarabine

Radiation: Total Body Irradiation

A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (...

This is a phase 1, multicenter, open-label study evaluating the safety and efficacy of ruxolitinib, steroids and lenalidomide among MM patients who currently show progressive disease.

Drug: Ruxolitinib Oral Tablet [Jakafi]

Drug: Lenalidomide

Drug: Methylprednisolone

Umbilical Cord Blood Transplantation From Unrelated Donors

This study is a single-center, treatment protocol with 4 possible preparative regimens, designed to validate the process of umbilical cord blood stem cell transplantation at our institution.

Radiation: Total Body Irradiation 1200 cGy

Radiation: Total Body Irradiation 200 cGy

Drug: Cyclophosphamide

Drug: Mesna

Procedure: Cord Blood Infusion

Drug: Busulfan

Drug: Fludarabine

Drug: Melphalan

An Open-Label, Multicenter, Phase 2 Study of Iopofosine I 131 (CLR 131) in Patients With Relapsed or...

Part A of this study evaluates iopofosine I 131 (CLR 131) in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom M...

Drug: Iopofosine I 131 single dose

Drug: Iopofosine I 131 multiple dose

Drug: Iopofosine I 131 fractionated dose

A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexameth...

A Phase 2, open-label, dose escalation study to evaluate the safety and efficacy of venetoclax in combination with carfilzomib-dexamethasone (Kd) in participants with relapsed or refractory MM and have received 1 to 3 prior lines of therapy. Part 4 ...

Drug: Carfilzomib

Drug: Venetoclax

Drug: Dexamethasone

A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose...

This is a multicenter, multi-country, open-label, Phase 1b/2a dose-escalation study consisting of two parts: dose escalation (Part 1) for CC-220 monotherapy, CC-220 in combination with DEX, CC-220 in combination with DEX and DARA, CC-220 in combinati...

Drug: CC-220

Drug: Dexamethasone

Drug: Daratumumab

Drug: Bortezomib

Drug: Carfilzomib

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug. NOTE: Due to ch...

Drug: Palbociclib

Drug: Sunitinib

Drug: Temsirolimus

Drug: Trastuzumab and Pertuzumab

Drug: Vemurafenib and Cobimetinib

Drug: Regorafenib

Drug: Olaparib

Drug: Pembrolizumab

Drug: Nivolumab and Ipilimumab

Drug: Abemaciclib

Drug: Talazoparib

Drug: Atezolizumab and PHESGO

Drug: Atezolizumab and Talazoparib

Drug: Entrectinib

Drug: Larotrectinib

Drug: Tucatinib plus Trastuzumab Subcutaneous (SC)

Drug: Futibatinib

A Phase 1 First in Human Study Evaluating the Safety, Tolerability, Pharmacokinetics and Pharmacodyn...

At least one dose level of AMG 176 will achieve acceptable safety and tolerability in participants with relapsed or refractory multiple myeloma and participants with relapsed or refractory acute myeloid leukemia

Drug: AMG 176

Drug: Azacitidine

Drug: Itraconazole

A Phase 1/2 Open-Label Study of the Safety, Tolerability and Efficacy of the Selective Inhibitor of ...

This is a first-in-human, multi-center, open-label clinical study with separate dose escalation (Phase 1) and expansion (Phase 2) stages to assess preliminary safety, tolerability, and efficacy of the second generation oral XPO1 inhibitor KPT-8602 in...

Drug: KPT-8602

Drug: ASTX727

Drug: Dexamethasone

A Phase I/II Open Label, Dose Escalation Study of Palifermin (Kepivance) in Persons Undergoing Unrel...

Background: - In allogeneic stem cell transplantation (SCT), stem cells are taken from a donor and given to a recipient. Sometimes the recipient s immune system destroys the donor s cells. Or donor immune cells attack the recipient s tissues, called...

Biological: Rituximab

Drug: Conditioning chemotherapy

Drug: TMS

Drug: FLAG

Drug: EPOCH-F

Procedure: Hematopoietic stem cell transplant

Drug: Palifermin

A Multi-ARM Phase Ib Study of SAR650984 (Isatuximab, an Anti-CD38 mAb) in Combination With Standard ...

This phase Ib trial studies the side effects and best dose of isatuximab when given together with carfilzomib with or without dexamethasone and lenalidomide in treating patients with multiple myeloma that has returned after a period of improvement (r...

Biological: Isatuximab

Drug: Carfilzomib

Drug: Dexamethasone

Administration of Tumor-Associated Antigen (TAA)-Specific Cytotoxic T-Lymphocytes to Patients With A...

This study is for patients that have a cancer called Multiple Myeloma, monoclonal gammopathy of undetermined significance (MGUS) or smoldering myeloma (SM). MGUS and SM have tumor cells that possess nearly identical properties to the cancer cells see...

Biological: TAA-specific CTLs

Biological: TAA-specific CTLs- fixed dose

A Phase I Study of the Combination of a Selective Inhibitor of Nuclear Export (SINE), Selinexor With...

This phase I trial studies the side effects and best dose of selinexor and carfilzomib when given together with dexamethasone in treating patients with multiple myeloma that has returned or does not respond to treatment. Drugs used in chemotherapy, s...

Drug: selinexor

Drug: carfilzomib

Drug: dexamethasone

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for the Treatment of ...

This is a treatment guideline for an unrelated umbilical cord blood transplant (UCBT) using a myeloablative preparative regimen for the treatment of hematological diseases, including, but not limited to acute leukemias. The myeloablative preparative ...

Drug: Fludarabine

Drug: Cyclophosphamide

Radiation: Total Body Irradiation

Drug: Cyclosporine A

Drug: Mycophenylate mofetil

Biological: Umbilical cord blood

Combined Haploidentical Reduced Intensity Bone Marrow and Kidney Transplantation for Patients With C...

The main purpose of this study is to examine the outcome of a combined bone marrow and kidney transplant from a partially matched related (haploidentical or "haplo") donor. This is a pilot study, you are being asked to participate because you have a ...

Procedure: Haploidentical Bone Marrow/Kidney

Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Trea...

The study will investigate the effects of adding carfilzomib to the combination of pomalidomide and dexamethasone in sequential dose escalation cohorts in patients with relapsed or refractory multiple myeloma. This portion of the study is complete. ...

Drug: Pomalidomide

Drug: Carfilzomib

Drug: dexamethasone

Drug: Daratumumab